NCT06720896View on ClinicalTrials.gov

A Phase 2, Controlled, Double Blind, Randomized and Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Blepharitis
Interventions
DRUG

APT-001 topical ophthalmic ointment (spinosad)

APT-001 topical ophthalmic ointment, administered once daily

DRUG

Vehicle control for APT-001 topical ophthalmic ointment

Vehicle control for APT-001 topical ophthalmic ointment, administered once daily

Trial Locations (2)

Unknown

Dr. Rudy Gutierrez Diaz Sede Central, Guatemala City

EyeScan, Imágenes Diagnósticas Oculares, S. A., Guatemala City

Sponsors
All Listed Sponsors
lead

Aperta Biosciences, LLC

INDUSTRY